START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as ...
COLUMBIA — During House Speaker Bobby Harrell’s weekly ETV program on tuesday, the Speaker and guests highlighted a resolution (H. 4823) that urges the Governor to apply for a non-compliant extension ...
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback